The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 23, 2022

Filed:

Dec. 09, 2017
Applicant:

The Uab Research Foundation, Birmingham, AL (US);

Inventors:

Lawrence S. Lamb, Jr., Birmingham, AL (US);

Antonio Di Stasi, Birmingham, AL (US);

G. Yancey Gillespie, Birmingham, AL (US);

Larisa Pereboeva, Birmingham, AL (US);

Assignee:

The UAB Research Foundation, Birmingham, AL (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); C07K 14/435 (2006.01); A61K 38/17 (2006.01); A61K 45/06 (2006.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01);
U.S. Cl.
CPC ...
C07K 14/43522 (2013.01); A61K 35/17 (2013.01); A61K 38/177 (2013.01); A61K 38/178 (2013.01); A61K 38/1767 (2013.01); A61K 38/1774 (2013.01); A61K 45/06 (2013.01); C07K 14/7051 (2013.01); C07K 14/7056 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/55 (2013.01); C07K 2319/74 (2013.01);
Abstract

The invention provides chimeric antigen receptor(s) (CAR(s)) that comprise a fusion protein of CTX or any functional variant thereof or a CTX-like peptide or any functional variant thereof as the extracellular antigen recognition moiety of the CAR. CAR(s) comprising CTX, a CTX-like peptide or functional variants of the foregoing are collectively referred to herein as 'CTX-CAR(s).' Such CTX-CAR(s) may further comprise additional moieties or domains in the extracellular domain, a transmembrane domain and at least one intracellular! signaling domain. Such CTX-CAR(s) may be expressed in a host cell, such as, but not limited to, an immune effector cell. The present invention also provides methods of treatment (such as, for example, methods for treating cancer) by providing to the patient in need thereof immune effector cells that are engineered to express a CTX-CAR described herein.


Find Patent Forward Citations

Loading…